none18noSarcomas are frequent tumors in children and young adults that, despite a relative chemosensitivity, show high relapse rates with up to 80% of metastatic patients dying in 5 years from diagnosis. The real ontogeny of sarcomas is still debated and evidences suggest they may derive from precursors identified within mesenchymal stromal/stem cells (MSC) fractions. Recent studies on sarcoma microenvironment additionally indicated that MSC could take active part in generation of a supportive stroma. Based on this knowledge, we conceived to use modified MSC to deliver tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) targeting different sarcoma histotypes. Gene modified MSC expressing TRAIL were cocultured with different oste...
New therapeutic approaches aim to eradicate tumours by expression of tumouricidal proteins in the tu...
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has...
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
Mesenchymal stem cells (MSCs) are able to infiltrate tumor tissues and thereby effectively deliver g...
New therapeutic approaches aim to eradicate tumours by expression of tumouricidal proteins in the tu...
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS patients have no...
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS patients have no...
New therapeutic approaches aim to eradicate tumours by expression of tumouricidal proteins in the tu...
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has...
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
International audienceEwing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor...
Mesenchymal stem cells (MSCs) are able to infiltrate tumor tissues and thereby effectively deliver g...
New therapeutic approaches aim to eradicate tumours by expression of tumouricidal proteins in the tu...
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS patients have no...
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS patients have no...
New therapeutic approaches aim to eradicate tumours by expression of tumouricidal proteins in the tu...
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has...
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has...